SI2742356T1 - Prediktorji pri zdravljenju raka - Google Patents

Prediktorji pri zdravljenju raka

Info

Publication number
SI2742356T1
SI2742356T1 SI201230563A SI201230563A SI2742356T1 SI 2742356 T1 SI2742356 T1 SI 2742356T1 SI 201230563 A SI201230563 A SI 201230563A SI 201230563 A SI201230563 A SI 201230563A SI 2742356 T1 SI2742356 T1 SI 2742356T1
Authority
SI
Slovenia
Prior art keywords
predictors
cancer treatment
cancer
treatment
Prior art date
Application number
SI201230563A
Other languages
English (en)
Inventor
Deborah Ricci
Weimin Li
Erin Devay Henitz
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of SI2742356T1 publication Critical patent/SI2742356T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • General Engineering & Computer Science (AREA)
SI201230563A 2011-08-11 2012-08-08 Prediktorji pri zdravljenju raka SI2742356T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161522596P 2011-08-11 2011-08-11
US201161560555P 2011-11-16 2011-11-16
PCT/US2012/049941 WO2013022935A1 (en) 2011-08-11 2012-08-08 Predictors for cancer treatment
EP12754124.1A EP2742356B1 (en) 2011-08-11 2012-08-08 Predictors for cancer treatment

Publications (1)

Publication Number Publication Date
SI2742356T1 true SI2742356T1 (sl) 2016-06-30

Family

ID=47668910

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201230563A SI2742356T1 (sl) 2011-08-11 2012-08-08 Prediktorji pri zdravljenju raka

Country Status (20)

Country Link
US (1) US9322066B2 (sl)
EP (1) EP2742356B1 (sl)
JP (1) JP6002222B2 (sl)
CN (1) CN103930785B (sl)
AU (1) AU2012294493B2 (sl)
CA (1) CA2844825A1 (sl)
CY (1) CY1117838T1 (sl)
DK (1) DK2742356T3 (sl)
ES (1) ES2586328T3 (sl)
HK (2) HK1199094A1 (sl)
HR (1) HRP20160851T1 (sl)
HU (1) HUE029295T2 (sl)
MX (1) MX357429B (sl)
PL (1) PL2742356T3 (sl)
PT (1) PT2742356E (sl)
RS (1) RS55053B1 (sl)
RU (1) RU2600026C2 (sl)
SI (1) SI2742356T1 (sl)
SM (1) SMT201600235B (sl)
WO (1) WO2013022935A1 (sl)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130346093A1 (en) * 2012-06-22 2013-12-26 Quintiles Transnational Corporation Systems and Methods for Analytics on Viable Patient Populations
US10795879B2 (en) 2012-06-22 2020-10-06 Iqvia Inc. Methods and systems for predictive clinical planning and design
WO2016004221A1 (en) * 2014-07-01 2016-01-07 Mayo Foundation For Medical Education And Research Methods and materials for identifying and treating mammals resistant to proteasome inhibitor treatments
JP6871851B2 (ja) 2014-09-10 2021-05-19 リテンズ オートモーティヴ パートナーシップ 捩りバネ力を使用する比例減衰式動力伝達デバイス
JP2019519548A (ja) * 2016-06-17 2019-07-11 ヴァリアン メディカル システムズ インコーポレイテッド 放射線処置と組み合わせた免疫調節剤
CN106845153A (zh) * 2016-12-29 2017-06-13 安诺优达基因科技(北京)有限公司 一种用于利用循环肿瘤dna样本检测体细胞突变的装置
CN106874710A (zh) * 2016-12-29 2017-06-20 安诺优达基因科技(北京)有限公司 一种用于利用肿瘤ffpe样本检测体细胞突变的装置
CN110462239B (zh) 2017-03-28 2022-05-10 利滕斯汽车合伙公司 在弹簧止挡部与阻尼构件之间具有选定的角度的隔离装置
EP3705584A1 (en) * 2019-03-05 2020-09-09 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method of identifying patients with bortezomib resistant multiple myeloma and other blood diseases

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693617A (en) 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6335358B1 (en) 1995-04-12 2002-01-01 President And Fellows Of Harvard College Lactacystin analogs
GB9623908D0 (en) 1996-11-18 1997-01-08 Hoffmann La Roche Amino acid derivatives
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
US6075150A (en) 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6831099B1 (en) 1999-05-12 2004-12-14 Yale University Enzyme inhibition
CA2435146C (en) 2001-01-25 2011-03-29 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Formulation of boronic acid compounds
WO2004053066A2 (en) 2002-12-06 2004-06-24 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
CN100366636C (zh) * 2004-12-08 2008-02-06 中国农业科学院畜牧研究所 猪生产及免疫性状相关蛋白，它的编码基因与应用
KR100653990B1 (ko) 2004-12-29 2006-12-05 주식회사 하이닉스반도체 포토마스크 데이터베이스 패턴의 불량 검사 방법
CA2611728A1 (en) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
US9500656B2 (en) 2006-08-10 2016-11-22 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
WO2009148528A2 (en) 2008-05-30 2009-12-10 Millennium Pharmaceuticals, Inc. Assessment of chromosomal alterations to predict clinical outcome of bortezomib treatment

Also Published As

Publication number Publication date
AU2012294493B2 (en) 2017-02-23
CA2844825A1 (en) 2013-02-14
HUE029295T2 (en) 2017-02-28
US20130216524A1 (en) 2013-08-22
EP2742356B1 (en) 2016-04-27
CN103930785A (zh) 2014-07-16
PL2742356T3 (pl) 2016-11-30
MX357429B (es) 2018-07-09
HK1199097A1 (zh) 2015-06-19
MX2014001619A (es) 2014-11-10
JP2014524571A (ja) 2014-09-22
SMT201600235B (it) 2016-08-31
ES2586328T3 (es) 2016-10-13
WO2013022935A1 (en) 2013-02-14
RU2014108986A (ru) 2015-09-20
HRP20160851T1 (hr) 2016-09-23
CY1117838T1 (el) 2017-05-17
HK1199094A1 (en) 2015-06-19
US9322066B2 (en) 2016-04-26
RS55053B1 (sr) 2016-12-30
EP2742356A1 (en) 2014-06-18
DK2742356T3 (en) 2016-05-23
JP6002222B2 (ja) 2016-10-05
CN103930785B (zh) 2016-05-18
PT2742356E (pt) 2016-06-06
AU2012294493A1 (en) 2014-02-20
RU2600026C2 (ru) 2016-10-20

Similar Documents

Publication Publication Date Title
IL267242B (en) Cancer treatment
HRP20160851T1 (hr) Prediktori za liječenje karcinoma
EP2635286A4 (en) METHOD FOR THE TREATMENT OF CANCER
HK1212617A1 (zh) 白癜風的治療
HK1185874A1 (zh) 用於治療癌症的新的 -氨基- -羥基-苯甲酰胺
IL222958A0 (en) Cancer treatment
IL228644A0 (en) Cancer treatment methods
HK1210023A1 (en) Cancer treatment
HRP20180875T1 (hr) Kombinacijska terapija raka jajnika
EP2934500A4 (en) COMBINATION THERAPY AGAINST CANCER
PL2855475T3 (pl) Alfa-karboliny do leczenia nowotworu
GB201106630D0 (en) Cancer therapy
GB201222563D0 (en) Cancer treatment
IL239231A0 (en) Combined cancer treatment
GB201116328D0 (en) Treatment for tumours
GB201118220D0 (en) Cancer therapy
GB201301168D0 (en) Cancer treatment
GB201019034D0 (en) Treatment for tumors